Nesa Marti

A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial

Ross A. Soo, Ji‐Youn Han, Urania Dafni et al. · Annals of Oncology · 2021 · 116 citations · Full text

Medicine, Oncology, Pharmacotherapy +10

Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project

Igor Letovanec, Stephen P. Finn, Panagiota Zygoura et al. · Journal of Thoracic Oncology · 2017 · 84 citations · Full text

Medicine, Cancer Biology, Oncology +7

Genes and proteins of the alternative steroid backdoor pathway for dihydrotestosterone synthesis are expressed in the human ovary and seem enhanced in the polycystic ovary syndrome

Nesa Marti, José A. Galván, Amit V. Pandey et al. · Molecular and Cellular Endocrinology · 2016 · 74 citations

Life Sciences, Endocrinology, Genetics +15

Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscape Project

Stephen P. Finn, Alfredo Addeo, Urania Dafni et al. · Journal of Thoracic Oncology · 2021 · 64 citations · Full text

Medicine, Genetics, Oncology +14

Resveratrol inhibits androgen production of human adrenocortical H295R cells by lowering CYP17 and CYP21 expression and activities

Nesa Marti, Nadia Bouchoucha, Kay‐Sara Sauter et al. · PLoS ONE · 2017 · 45 citations · Full text

Life Sciences, Biochemistry, Endocrinology +17